Literature DB >> 19067104

A case of inclusion body myositis responsive to prednisolone therapy.

Rahul Kalla1, Majella Soumakiyan, Stephen Tuck.   

Abstract

Inclusion body myositis, although rare, is the commonest cause of myopathy in patients aged over 50 years. The suggested pathogenesis remains uncertain and its prognosis remains poor. There have been select case reports of its association with an inflammatory etiology and it is postulated that this group of patients respond better to immunosuppressive therapy. We therefore report a rare case of inclusion body myositis that responded well to immunosuppressive therapy. We also report the possibility of its association with infliximab therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19067104     DOI: 10.1007/s10067-008-1047-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  9 in total

1.  Epidemiology of inclusion body myositis in the Netherlands: a nationwide study.

Authors:  U A Badrising; M Maat-Schieman; S G van Duinen; F Breedveld; P van Doorn; B van Engelen; F van den Hoogen; J Hoogendijk; C Höweler; A de Jager; F Jennekens; P Koehler; H van der Leeuw; M de Visser; J J Verschuuren; A R Wintzen
Journal:  Neurology       Date:  2000-11-14       Impact factor: 9.910

2.  Polymyositis associated with infliximab treatment for rheumatoid arthritis.

Authors:  J Musiał; A Undas; M Celińska-Lowenhoff
Journal:  Rheumatology (Oxford)       Date:  2003-12       Impact factor: 7.580

Review 3.  Inclusion-body myositis: clinical, diagnostic, and pathologic aspects.

Authors:  W King Engel; Valerie Askanas
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

Review 4.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

Review 5.  Inclusion body myositis and myopathies.

Authors:  R C Griggs; V Askanas; S DiMauro; A Engel; G Karpati; J R Mendell; L P Rowland
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

6.  Inclusion body myositis. Observations in 40 patients.

Authors:  B P Lotz; A G Engel; H Nishino; J C Stevens; W J Litchy
Journal:  Brain       Date:  1989-06       Impact factor: 13.501

7.  Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis.

Authors:  Louis W C Liu; Mark Tarnopolsky; David Armstrong
Journal:  Can J Gastroenterol       Date:  2004-06       Impact factor: 3.522

Review 8.  Inclusion body myositis in connective tissue disorders: case report and review of the literature.

Authors:  C T Derk; F B Vivino; L Kenyon; S Mandel
Journal:  Clin Rheumatol       Date:  2003-10       Impact factor: 2.980

9.  Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM.

Authors:  Nizar Chahin; Andrew G Engel
Journal:  Neurology       Date:  2007-09-19       Impact factor: 9.910

  9 in total
  1 in total

1.  Inclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNFalpha and rituximab.

Authors:  Stefan Vordenbäumen; Eva Neuen-Jacob; Jutta Richter; Matthias Schneider
Journal:  Clin Rheumatol       Date:  2010-01-27       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.